metastatic breast cancer

Roche reports positive Phase III data for breast cancer therapy
Roche reports positive Phase III data for breast cancer therapy
Clinical Trials Arena
Roche
clinical trials
inavolisib
metastatic breast cancer
breast cancer
Flag link:
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
BioSpace
BriaCell Therapeutics
Bria-IMT
immune checkpoint inhibitors
metastatic breast cancer
Flag link:
Odonate Pulls MBC Drug Candidate and Closes Shop
Odonate Pulls MBC Drug Candidate and Closes Shop
BioSpace
Odonate Therapeutics
Tesetaxel
metastatic breast cancer
Flag link:
Athenex features real patients in first oncology campaign as it readies key breast cancer filing
Athenex features real patients in first oncology campaign as it readies key breast cancer filing
Fierce Pharma
oncology
Athenex
metastatic breast cancer
patients
Flag link:
Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial
Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial
Pharmaceutical Business Review
Odonate Therapeutics
metastatic breast cancer
clinical trials
Tesetaxel
Flag link:
Lilly cancer push boosted by survival benefit to key drug
Lilly cancer push boosted by survival benefit to key drug
Biopharma Dive
Eli Lilly
Verzenio
metastatic breast cancer
clinical trials
Flag link:
AstraZeneca's share dilution gamble on Daiichi drug pays off
AstraZeneca's share dilution gamble on Daiichi drug pays off
Biopharma Dive
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
metastatic breast cancer
Flag link:
MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer
MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer
Endpoints
Macrogenics
metastatic breast cancer
margetuximab
clinical trials
Flag link:
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
CP Wire
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
metastatic breast cancer
FDA
EMA
priority review
Flag link:
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
Flag link:
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Endpoints
Roche
taselisib
fulvestrant
metastatic breast cancer
ASCO 2018
Flag link:
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
ASCO 2018
taselisib
fulvestrant
metastatic breast cancer
estrogen-receptor cancer
Flag link:
Breast Cancer Cells Use In-House Recycling To Survive After Spreading
Breast Cancer Cells Use In-House Recycling To Survive After Spreading
Forbes
breast cancer
metastatic breast cancer
autophagy
Novartis
Pfizer
Flag link:
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
CP Wire
AstraZeneca
Merck
Lynparza
metastatic breast cancer
AACR
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
Flag link:
A New PARP Drug For Breast Cancer
A New PARP Drug For Breast Cancer
Forbes
PARP inhibitors
breast cancer
metastatic breast cancer
talazoparib
Pfizer
Flag link:
In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms
In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms
Forbes
Novartis
Kisqali
metastatic breast cancer
Flag link:
Roche ditches work on NewLink’s IDO cancer candidate
Roche ditches work on NewLink’s IDO cancer candidate
Fierce Biotech
Roche
NewLink Genetics
indoximod
metastatic breast cancer
Flag link:
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Yahoo
Eli Lilly
Boehringer Ingelheim
clinical trials
metastatic breast cancer
abemaciclib
BI 836845
Flag link:

Pages